GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis

NCT01451905 · Unknown status

Last updated 2026-05-28

This clinical trial is studying the effects of liraglutide, a GLP-1 receptor medication, on skin changes in people with psoriasis compared to those without the condition.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind study

Participants 12 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2011-08 · est. completion 2012-12

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01451905 ↗

Description as written by the study sponsor.

To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease

Treatments tested

Liraglutide Drug

Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
Placebo Drug

The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only

Main thing measured	Changes in PASI and DLQI
Sponsor	University Hospital, Gentofte, Copenhagen
Conditions studied	Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01451905 ↗